Severe Adverse Events in Neoadjuvant Therapy of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Phase 3 Trials

Dr. André Mattar

Neoadjuvant therapy (NAT) is standard treatment for triple-negative breast cancer (TNBC) but toxicity is a major concern. This study aimed to assess the incidence and risk of grade ≥3 adverse events (AEs) associated with NAT in non-metastatic TNBC. Methods:We performed a systematic review and meta-analysis registered in PROSPERO (CRD42024562785). Four databases were searched for randomized […]